Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Shares of Merck slid Tuesday after the ...

Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the ...

Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the broader biopharma industry. For the full year, Merck now expects sales ...

(Reuters) -Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its effort to diversify ahead of patent loss for its blockbuster cancer ...

Merck (MRK) is set to report Q4 earnings on Tuesday, February 3, before market open. Wall Street expects EPS of $2.01, representing 16.9% year-over-year growth, on revenue of $16.21B, up 3.8% Y/Y.

Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...